NASDAQ:NK - Nantkwest Stock Price, Forecast & News

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest Inc (NASDAQ:NK) announced its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The biotechnology company earned $0.01 million during the quarter. Nantkwest had a negative return on equity of 44.91% and a negative net margin of 164,604.89%. View Nantkwest's Earnings History.

Nantkwest is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Nantkwest.

1 equities research analysts have issued 12 month price targets for Nantkwest's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Nantkwest's stock price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 84.1%. View Analyst Price Targets for Nantkwest.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Nantkwest.

News stories about NK stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nantkwest earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the company's share price in the near term. View News Stories for Nantkwest.

Nantkwest saw a increase in short interest in January. As of January 15th, there was short interest totalling 2,830,000 shares, an increase of 34.1% from the December 31st total of 2,110,000 shares. Based on an average daily volume of 803,300 shares, the days-to-cover ratio is presently 3.5 days. Approximately 31.0% of the shares of the stock are sold short. View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), Krystal Biotech (KRYS), Twist Bioscience (TWST) and Adverum Biotechnologies (ADVM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Immunomedics (IMMU), Novavax (NVAX), Vodafone Group (VOD), NovaBay Pharmaceuticals (NBY), Fate Therapeutics (FATE), Ocular Therapeutix (OCUL) and Opko Health (OPK).

(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.66%), Charles Schwab Investment Management Inc. (0.17%), Credit Suisse AG (0.13%), Laurion Capital Management LP (0.02%), Oppenheimer & Co. Inc. (0.02%) and State Street Corp (0.01%). Company insiders that own Nantkwest stock include John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.

NK stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., State Street Corp, UBS Group AG, Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Nantkwest.

NK stock was bought by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, Charles Schwab Investment Management Inc., Laurion Capital Management LP, Alpine Global Management LLC and National Asset Management Inc.. View Insider Buying and Selling for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NK stock can currently be purchased for approximately $6.30.

Nantkwest has a market capitalization of $619.73 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Nantkwest employs 161 workers across the globe.View Additional Information About Nantkwest.

The official website for Nantkwest is http://www.nantkwest.com/.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]